These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 31049900)
21. Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients. Gluba-Brzozka A; Franczyk B; Bartnicki P; Rysz-Gorzyn Ska M; Rysz J Curr Vasc Pharmacol; 2017; 15(2):123-134. PubMed ID: 27774887 [TBL] [Abstract][Full Text] [Related]
22. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. Galsgaard J; Persson F; Hansen TW; Jorsal A; Tarnow L; Parving HH; Rossing P Kidney Int; 2017 Nov; 92(5):1242-1248. PubMed ID: 28712855 [TBL] [Abstract][Full Text] [Related]
23. Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD. Matsui K; Kamijo-Ikemori A; Imai N; Sugaya T; Yasuda T; Tatsunami S; Toyama T; Shimizu M; Furuichi K; Wada T; Shibagaki Y; Kimura K Clin Exp Nephrol; 2016 Apr; 20(2):195-203. PubMed ID: 26189083 [TBL] [Abstract][Full Text] [Related]
24. Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients. El-Agroudy AE; El-Baz A Clin Exp Nephrol; 2010 Apr; 14(2):152-7. PubMed ID: 20101431 [TBL] [Abstract][Full Text] [Related]
25. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. deFilippi C; Wasserman S; Rosanio S; Tiblier E; Sperger H; Tocchi M; Christenson R; Uretsky B; Smiley M; Gold J; Muniz H; Badalamenti J; Herzog C; Henrich W JAMA; 2003 Jul; 290(3):353-9. PubMed ID: 12865376 [TBL] [Abstract][Full Text] [Related]
26. The impact of dialysis type on biomarkers for cardiovascular diseases. Sahinarslan A; Güz G; Mutluay R; Okyay K; Demirtaş C; Paşaoğlu H; Yalçın R Turk Kardiyol Dern Ars; 2011 Sep; 39(6):456-62. PubMed ID: 21918314 [TBL] [Abstract][Full Text] [Related]
27. Relations of advanced glycation endproducts and dicarbonyls with endothelial dysfunction and low-grade inflammation in individuals with end-stage renal disease in the transition to renal replacement therapy: A cross-sectional observational study. Martens RJH; Broers NJH; Canaud B; Christiaans MHL; Cornelis T; Gauly A; Hermans MMH; Konings CJAM; van der Sande FM; Scheijen JLJM; Stifft F; Wirtz JJJM; Kooman JP; Schalkwijk CG PLoS One; 2019; 14(8):e0221058. PubMed ID: 31408493 [TBL] [Abstract][Full Text] [Related]
28. Changes in the inflammatory and oxidative stress markers during a single hemodialysis session in patients with chronic kidney disease. Sangeetha Lakshmi B; Harini Devi N; Suchitra MM; Srinivasa Rao PVLN; Siva Kumar V Ren Fail; 2018 Nov; 40(1):534-540. PubMed ID: 30277113 [TBL] [Abstract][Full Text] [Related]
29. Prognostic value of plasma myeloperoxidase in ESRD patients. Wang AY; Lam CW; Chan IH; Wang M; Lui SF; Sanderson JE Am J Kidney Dis; 2010 Nov; 56(5):937-46. PubMed ID: 20638167 [TBL] [Abstract][Full Text] [Related]
30. C-reactive protein in end-stage renal disease: are there reasons to measure it? Stenvinkel P; Lindholm B Blood Purif; 2005; 23(1):72-8. PubMed ID: 15627740 [TBL] [Abstract][Full Text] [Related]
32. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Pawlak K; Domaniewski T; Mysliwiec M; Pawlak D Atherosclerosis; 2009 May; 204(1):309-14. PubMed ID: 18823890 [TBL] [Abstract][Full Text] [Related]
33. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients. Afzali B; Bakri RS; Bharma-Ariza P; Lumb PJ; Dalton N; Turner NC; Wierzbicki AS; Crook MA; Goldsmith DJ J Nephrol; 2003; 16(4):540-5. PubMed ID: 14696756 [TBL] [Abstract][Full Text] [Related]
34. The effect of treatment with N-acetylcysteine on the serum levels of C-reactive protein and interleukin-6 in patients on hemodialysis. Saddadi F; Alatab S; Pasha F; Ganji MR; Soleimanian T Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):66-72. PubMed ID: 24434384 [TBL] [Abstract][Full Text] [Related]
35. Plasma myeloperoxidase, NT-proBNP, and troponin-I in patients on CAPD compared with those on regular hemodialysis. Al-Hweish A; Sultan SS; Mogazi K; Elsammak MY Hemodial Int; 2010 Jul; 14(3):308-15. PubMed ID: 20597992 [TBL] [Abstract][Full Text] [Related]
36. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Busch M; Franke S; Müller A; Wolf M; Gerth J; Ott U; Niwa T; Stein G Kidney Int; 2004 Jul; 66(1):338-47. PubMed ID: 15200442 [TBL] [Abstract][Full Text] [Related]
37. Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: improvements by L-arginine intake. El-Mesallamy HO; Abdel Hamid SG; Gad MZ Kidney Blood Press Res; 2008; 31(3):189-95. PubMed ID: 18511874 [TBL] [Abstract][Full Text] [Related]
38. Myeloperoxidase is an early biomarker of inflammation and cardiovascular risk in prepubertal obese children. Olza J; Aguilera CM; Gil-Campos M; Leis R; Bueno G; Martínez-Jiménez MD; Valle M; Cañete R; Tojo R; Moreno LA; Gil A Diabetes Care; 2012 Nov; 35(11):2373-6. PubMed ID: 22912422 [TBL] [Abstract][Full Text] [Related]
39. Increased cardiac troponin T and C-reactive protein levels in end-stage renal disease are associated with obstructive sleep apnea. Koehnlein T; Schmidt A; Moesenthin M; Dierkes J; Neumann KH; Welte T Clin Nephrol; 2009 Jan; 71(1):50-8. PubMed ID: 19203550 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of plasma concentrations of homocysteine, IL-6, TNF-alpha, hs-CRP, and total antioxidant capacity in patients with end-stage renal failure. Babaei M; Dashti N; Lamei N; Abdi K; Nazari F; Abbasian S; Gerayeshnejad S Acta Med Iran; 2014; 52(12):893-8. PubMed ID: 25530051 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]